Phaseline

Targets › CFTR

CFTR (Cystic fibrosis transmembrane conductance regulator): drug programs, companies and trials

13 programs from 10 companies in 18 trials: 6 Phase 2, 6 Phase 3, 3 Phase 4, 3 Phase 1; Respiratory, Gastroenterology, Other; next expected readout Nov 2026.

Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis. Mediates the transport of chloride ions across the cell membrane. (UniProt, P13569)

Open in Phaseline: the race on CFTR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vertex PharmaceuticalsIvacaftor
Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator
CFTRPhase 3Cystic Fibrosis; Cystic Fibrosis (CF)Apr 2027
Vertex PharmaceuticalsTezacaftor
Cystic fibrosis transmembrane conductance regulator positive modulator
CFTRPhase 3Cystic Fibrosis; Cystic Fibrosis (CF)Apr 2027
Tehran University of Medical SciencesN-Acetylcysteine
Mucolytic agent and antioxidant; breaks disulfide bonds in mucoproteins and provides antio
CFTRPhase 3Oral Mucositis–
Vertex PharmaceuticalsVX-121/TEZ/D-IVA
CFTR modulator combination: VX-121 (CFTR potentiator) + tezacaftor (CFTR corrector) + deut
CFTRPhase 3Cystic Fibrosis–
ReCode TherapeuticsRCT2100
CFTR mRNA therapeutic
CFTRPhase 2Cystic FibrosisNov 2026
Napo PharmaceuticalsCrofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Microvillus Inclusion DiseaseDec 2026
Napo TherapeuticsCrofelemer
Cystic fibrosis transmembrane conductance regulator inhibitor; Anoctamin-1 blocker
CFTR, ANO1Phase 2Short Bowel SyndromeMar 2027
QanatpharmaLumacaftor
Cystic fibrosis transmembrane conductance regulator stabiliser
CFTRPhase 2Heart Failure With Reduced Ejection FractionMay 2027
4D Molecular Therapeutics4D-710
AAV gene therapy delivering human CFTR with regulatory domain deletion (CFTRΔR)
CFTRPhase 2Cystic Fibrosis LungJun 2027
Arcturus TherapeuticsARCT-032
CFTR mRNA formulated in lipid nanoparticles
CFTRPhase 2Cystic FibrosisJun 2027
Krystal BiotechKB407
Replication-defective HSV-1 expressing full-length human CFTR
CFTRPhase 1Cystic FibrosisDec 2026
Boehringer IngelheimBI 3720931 (Lenticlair™-ON)
Gene therapy for cystic fibrosis
CFTRPhase 1Cystic FibrosisOct 2040
Vertex PharmaceuticalsVX-522
mRNA therapy encoding CFTR
CFTRPhase 1Cystic Fibrosis–

Conditions

Cystic Fibrosis (11) Cystic Fibrosis (CF) (2) Microvillus Inclusion Disease (1) Cystic Fibrosis Lung (1) Short Bowel Syndrome (1) Heart Failure With Reduced Ejection Fraction (1) Oral Mucositis (1)

Modalities

small molecule (8), protein or peptide (3), other (1), mixed (1)

Companies

Vertex Pharmaceuticals (4) Napo Pharmaceuticals (1) 4D Molecular Therapeutics (1) ReCode Therapeutics (1) Napo Therapeutics (1) Qanatpharma (1) Krystal Biotech (1) Boehringer Ingelheim (1) Arcturus Therapeutics (1) Tehran University of Medical Sciences (1)

Related targets

ANO1 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.